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A 2014 report evaluating accuracy of serologic testing for 
transfusion-transmissible viruses at African blood center labo-
ratories found sensitivities of 92%, 87%, and 90% for detect-
ing infections with human immunodeficiency virus (HIV), 
hepatitis B virus (HBV), and hepatitis C virus (HCV), respec-
tively (1). Following substantial investments in national blood 
transfusion service (NBTS) laboratories, in 2017 investigators 
tested proficiency at 84 blood center laboratories (29 NBTS and 
55 non-NBTS) in seven African countries. A blinded panel of 25 
plasma samples was shipped to each participating laboratory for 
testing with their usual protocols based on rapid diagnostic tests 
(RDTs) (2) and third and fourth generation enzyme immunoas-
says (EIA-3 and EIA-4). Sensitivity and specificity were estimated 
using separate regression models that clustered assays by labora-
tory and adjusted for assay type and NBTS laboratory status. 
Mean specificities were ≥95% for all three viruses; however, mean 
sensitivities were 97% for HIV-positive, 76% for HBV-positive, 
and 80% for HCV-positive samples. Testing sensitivities for all 
viruses were high when EIA-3 assays were used (≥97%). Lower 
sensitivities for HBV-positive samples and HCV-positive samples 
were associated with assay types other than EIA-3, used primar-
ily by non-NBTS laboratories. Proficiency for HIV testing has 
improved following international investments, but proficiency 
remains suboptimal for HBV and HCV testing. In sub-Saharan 
African blood centers, the quality of rapid tests used for HBV 
and HCV screening needs to be improved or their use discour-
aged in favor of EIA-3 tests.
This cross-sectional study of blood transfusion laboratories 
was conducted in Ghana, Kenya, Malawi, Mozambique, 
Nigeria, Rwanda, and Tanzania during February–September 
2017. A stratified sampling strategy targeting all NBTS labo-
ratories and 10 non-NBTS laboratories per country (except 
Rwanda which has no non-NBTS laboratories) was used. 
Within each country, all non-NBTS laboratories were sorted 
by number of blood units tested annually, and five laborato-
ries were chosen randomly from strata above and below the 
median. Assay types in use at study laboratories were RDT; 
EIA-3, which detects antibody or antigen; and EIA-4, which 
detects both antigen and antibody. Characteristics of partici-
pating NBTS and non-NBTS laboratories were compared by 
country, prevalence of assay types, and measures of laboratory 
expertise, such as annual volume of specimens tested.
Panels of 25 challenge specimens were prepared and char-
acterized by the Institut National de la Transfusion Sanguine 
(Paris, France). Each panel included seven negative controls; 
seven specimens that contained HIV antigen and anti-HIV 
antibody (six HIV-1 and one HIV-2) (HIV-positive samples); 
six specimens containing hepatitis B surface antigen (con-
firmed by neutralization assay and quantified) (HBV-positive 
samples); and five specimens that contained HCV RNA and 
anti-HCV antibody (HCV-positive samples). All positive chal-
lenge specimens included viral genotypes that were specific to 
Africa. Plasma specimens were diluted with uninfected plasma 
to obtain specific antigen or antibody concentrations. The 
panels were confirmed to match their labels (Supplementary 
Table, https://stacks.cdc.gov/view/cdc/82012) at the Institut 
National de la Transfusion Sanguine, coded to allow for blinded 
testing, and sent to national coordinators who distributed them 
to participating laboratories while maintaining the cold chain.
Laboratories tested each challenge specimen in the panel 
using three assays, each designed to detect infection with HIV, 
HBV, or HCV, and reported findings for each assay. The pri-
mary study outcome was classification of each assay finding as 
correct or incorrect relative to each specimen’s true infection 
status; classification was done at the unblinded data analysis 
center. Sensitivity (correct detection of infection-positive status 
whether by antibody, antigen, or RNA) was estimated using 
approximately 25% of specimens for which the challenge 
virus matched the assay virus (seven HIV, six HBV, and five 
HCV), and specificity (correct detection of infection-negative 
status) was estimated using approximately 75% of specimens 
for which the challenge virus (or control) did not match the 
assay virus (18 HIV, 19 HBV, and 20 HCV).
The investigators used separate generalized estimating 
equation logit-binomial models to estimate mean sensitivity 
and specificity and 95% confidence intervals (CIs), each as a 
function of the three assay viruses (HIV, HBV, and HCV), 
clustering outcomes within laboratories. Multivariable models 
added NBTS status, assay type (RDT, EIA-3, or EIA-4), and 
all two-way interaction terms to the unadjusted model. The 
unadjusted model of specificity also included the identity of 
the challenge virus. All analyses were performed using SAS 
software (version 9.4; SAS Institute).
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Laboratory characteristics. Among the seven countries, 
the number of participating laboratories ranged from one 
(Rwanda) to 20 (Nigeria), and the proportion that were NBTS 
laboratories ranged from 9% (Malawi and Mozambique) to 
100% (Rwanda) (Table 1). Five non-NBTS laboratories (two 
each in Tanzania and Ghana and one in Kenya) did not partici-
pate, citing lack of reagents as the reason. Of 84 participating 
laboratories, 70 provided 100% of findings (25 specimens × 
three assays per laboratory), eight provided 93%, and six (all 
non-NBTS) provided 46%.
Among NBTS laboratories, 90% used EIA-3 or EIA-4 
assays, whereas among non-NBTS laboratories, 78%–82% 
used RDT assays. NBTS centers tested approximately 10 times 
more blood units than did non-NBTS laboratories, and higher 
proportions of NBTS than non-NBTS laboratories produced 
blood components (66% versus 35%) and received blood 
primarily from volunteer donors (100% versus 60%).
Sensitivity. Unadjusted mean sensitivity for detecting 
HIV-positivity was 97% (95% CI = 95%–98%); for detect-
ing HBV-positivity was 76% (95% CI = 71%–81%); and for 
detecting HCV-positivity was 80% (95% CI = 75%–86%) 
(Table 2). Sensitivity exceeded 90% for HIV-positive detec-
tion in all seven countries; however, this level of sensitivity 
for identifying HBV-positive specimens was reached only in 
Kenya and Rwanda, and for HCV-positive specimens, only in 
Kenya, Mozambique, and Rwanda (p<0.001). At NBTS labo-
ratories, all three assays’ sensitivities to their respective target 
viruses exceeded 92%; however, at non-NBTS laboratories, 
sensitivity to HBV-positive was 66% and to HCV-positive 
was 74% (p<0.001). Statistically significantly higher levels 
of testing sensitivity were observed in laboratories that tested 
more blood donations per year (p = 0.006), produced more 
components per year (p = 0.026), and had higher percentages 
of donors who were volunteers (p = 0.013). Testing sensitivity 
was not associated with the number of laboratory personnel.
Based on the multivariable model, adjusted sensitivities 
uniformly exceeded 96% when EIA-3 was used; however, the 
sensitivity of EIA-4 to detect HCV-positivity was <85%, and 
RDT assay sensitivities to detect HBV- and HCV-positivity 
were <71%. Sensitivity for detecting HIV-positivity was 
≥95% regardless of laboratory or assay type. Sensitivity varied 
significantly among assay types (p = 0.011) but not among 
assay target viruses (p = 0.30) or between NBTS laboratory 
status (p = 0.81), and none of the three pairwise interaction 
effects was statistically significant (p≥0.25). These findings are 
reflected by observed sensitivity proportions (Figure) that show 
that EIA-3 assays performed equally well or better than others 
for detecting HIV-, HBV-, and HCV-positivity, regardless of 
NBTS status.
Specificity. Unadjusted mean testing specificity was 95% 
(95% CI = 93%–97%) for HIV-negative specimens, 96% 
(95% CI = 93%–98%) for HBV-negative specimens, and 
95% (90%–98%) for HCV-negative specimens. Across all 
assay target viruses, mean specificity was 90%–92% in three 
countries (Malawi, Mozambique, and Tanzania) and ≥98% in 
the other four countries.
TABLE 1. Characteristics of participating blood centers and their 
laboratories by National Blood Transfusion Service (NBTS) status — 
seven African countries, 2017
Characteristic
No. (%)
Non-NBTS 
laboratories*  
(N = 55)
NBTS  
laboratories  
(N = 29)
Country
Ghana 8 (73) 3 (27)
Kenya 9 (60) 6 (40)
Malawi 10 (91) 1 (9)
Mozambique 10 (91) 1 (9)
Nigeria 10 (50) 10 (50)
Rwanda 0 (0) 1 (100)
Tanzania 8 (53) 7 (47)
Type of HIV assay evaluated
Rapid diagnostic test 45 (82) 3 (10)
EIA-3 2 (4) 4 (14)
EIA-4 8 (15) 22 (76)
Type of HBV assay evaluated†
Rapid diagnostic test 44 (80) 3 (10)
EIA-3 8 (15) 26 (90)
Unknown 3 (5) 0 (0)
Type of HCV assay evaluated†
Rapid diagnostic test 43 (78) 3 (10)
EIA-3 6 (11) 17 (59)
EIA-4 1 (2) 9 (31)
Unknown 5 (9) 0 (0)
Blood units assayed per year, 
median (25th, 75th 
percentiles)
1,100  
(192, 2,657)
11,000  
(3,303, 22,800)
Blood units produced per year
0 36 (65) 10 (34)
80–4,999 11 (20) 7 (24)
5,000–78,800 7 (13) 12 (41)
Percentage of collections from 
volunteer donors, median 
(25th, 75th percentiles)
10 (5, 60) 85 (75, 100)
No. of laboratory personnel, 
median (25th, 75th 
percentiles)
8 (5, 14) 4 (4, 7)
Director has MD or PhD 12 (22) 7 (24)
Participates in EQAS program 41 (75) 26 (90)
Abbreviations: EIA-3 = third generation enzyme immunoassay; EIA-4 = fourth 
generation enzyme immunoassay; EQAS = external quality assurance services; 
HBV = hepatitis B virus; HCV = hepatitis C virus; HIV = human immunodeficiency virus.
* Rwanda had no non-NBTS laboratories. Other participating countries had 10 
each; in total, five failed to provide results, citing lack of reagents.
† Sensitivity evaluations for assay targets HIV, HBV, and HCV were based on 84, 
81, and 79 laboratories, respectively, because no assay was reported for HBV-
positive specimens (three laboratories) and HCV-positive specimens 
(five laboratories).
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TABLE 2. Sensitivity* for detecting evidence of infection with human 
immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C 
virus (HCV), by selected characteristics of 84 laboratories — seven 
African countries, 2017
Characteristic
Assay target virus (no. of laboratories†)
p-value§
Mean % (95% CI)
HIV (n = 84) HBV (n = 81) HCV (n = 79)
Overall, 
unadjusted
96.6 (95.0–98.1) 75.8 (70.8–81.2) 80.2 (74.7–86.2) —
Country¶
Ghana 93.5 (87.8–96.6) 58.5 (52.9–63.8) 70.9 (50.8–85.2) <0.001
Kenya 99.0 (93.8–99.9) 93.3 (84.2–97.4) 96.0 (89.3–98.6)
Malawi 98.7 (92.0–99.8) 60.6 (47.4–72.4) 60.0 (43.2–74.7)
Mozambique 98.7 (91.9–99.8) 54.7 (42.1–66.8) 94.0 (85.1–97.7)
Nigeria 98.5 (94.7–99.6) 82.5 (69.6–90.7) 78.8 (61.6–89.6)
Rwanda 100 100 100
Tanzania 90.5 (83.1–94.8) 84.3 (69.6–92.7) 75.4 (63.4–84.4)
Assay type
Rapid 95.0 (91.9–96.9) 59.8 (54.7–64.6) 70.5 (61.1–78.4) <0.001
EIA-3 97.7 (84.7–99.7) 98.0 (91.4–99.6) 96.9 (92.2–98.8)
EIA-4 99.0 (96.8–99.7) (Not used) 84.4 (74.3–91.0)
NBTS
No 95.5 (92.8–97.3) 66.2 (60.2–71.7) 73.8 (64.7–81.2) <0.001
Yes 98.5 (95.8–99.5) 93.0 (83.4–97.3) 91.8 (86.7–95.0)
Blood units tested per year**
1,000 96.6 (94.7–97.8) 75.3 (69.8–80.2) 79.5 (72.9–84.8) 0.006
3,162 97.1 (95.3–98.3) 79.3 (73.6–84.1) 82.0 (75.6–87.1)
10,000 97.6 (95.7–98.7) 82.8 (76.6–87.6) 84.3 (77.5–89.4)
Components produced per year**
None 95.5 (92.4–97.4) 73.3 (65.9–79.5) 74.4 (65.1–82.0) 0.026
1,000 blood 
units
97.6 (95.4–98.7) 78.8 (71.3–84.4) 85.2 (78.3–90.1)
10,000 blood 
units
98.0 (95.4–99.2) 80.5 (70.7–87.6) 87.8 (79.9–92.9)
Percentage of donors who are volunteers
1–24 96.2 (92.8–98.0) 69.3 (61.7–75.9) 69.8 (57.8–79.6) 0.013
25–74 94.4 (88.9–97.3) 64.2 (51.4–75.2) 89.2 (79.3–94.6)
75–100 98.2 (94.3–99.4) 89.8 (81.0–94.8) 85.3 (76.0–91.4)
No. of laboratory personnel
1–6 97.6 (95.4–98.8) 74.7 (66.0–81.8) 81.7 (73.2–87.9) 0.36
7–54 95.3 (91.7–97.4) 77.9 (70.7–83.7) 78.1 (67.7–85.9)
Abbreviations: CI = confidence interval; EIA-3 = third generation enzyme 
immunoassay; EIA-4 = fourth generation enzyme immunoassay; NBTS = national 
blood transfusion service.
 * Based on univariate models.
 † Because HBV- and HCV-positive specimens were not assayed by three and 
five laboratories, respectively, sensitivity evaluations for assay targets HIV, 
HBV, and HCV were based on 84, 81, and 79 laboratories, respectively.
 § P-values report statistical significance of associations of sensitivity with the 
interaction between assay virus and laboratory characteristics.
 ¶ Model excluded Rwanda and excluded the interaction term. P-value reports 
statistical significance of association of sensitivity with country.
 ** Characteristic was analyzed on the log-10 scale. Mean sensitivity was 
estimated at the values shown.
Adjusted estimates based on the multivariable model showed 
that the targeted assays varied in specificity by assay type 
(p = 0.054) and interaction with NBTS status (p = 0.058). 
Specificity was relatively low at non-NBTS laboratories for 
RDT assays targeting HCV or HIV and at NBTS laboratories 
for EIA-4 assays targeting HIV (Figure).
Summary
What is already known about this topic?
Substantial international investments have been made in 
African national blood transfusion services (NBTS) following 
reports of deficiencies in viral marker screening at African blood 
center laboratories.
What is added by this report?
Standardized proficiency testing conducted in seven African 
countries during 2017 found that proficiency in human 
immunodeficiency virus testing has improved, but testing 
proficiency for hepatitis B virus (HBV) and hepatitis C virus 
(HCV) needs to be improved.
What are the implications for public health practice?
Most poor performance in hepatitis virus testing can be 
attributed to the use of rapid tests rather than the non-NBTS 
setting of the laboratories. Remediation should be focused on 
improving the quality of rapid tests or avoiding their use.
Discussion
This investigation of testing proficiency of targeted assays 
for HIV, HBV, and HCV found specificities to be high overall, 
with clinically negligible variations by NBTS status or assay 
type. In contrast, clinically important variation in sensitivi-
ties within and between assay targets was found. The finding 
that non-EIA-3 tests had lower sensitivity than did other 
assay types for detecting HBV- and HCV-positive specimens 
but not HIV-positive specimens is consistent with findings 
from previous studies (1–4). As noted, variation in testing 
proficiency for sensitivity among countries primarily reflects 
variation among assay types rather than between NBTS and 
non-NBTS laboratories.
This study found higher sensitivity for detecting HIV-
positivity but lower sensitivity for detecting HBV- and HCV-
positivity than is generally associated with the use of RDTs, 
compared with previous studies using similar methods (1,2). 
These results suggest that RDT assays targeting HIV perform 
better or have better quality assurance than do RDT assays 
targeting the hepatitis viruses. The poorer performance of RDT 
assays for detecting HBV- and HCV-positivity is most likely 
attributable to the quality of the assays themselves, because 
deficiency in performing the tests could have been signaled 
by lower mean accuracy at non-NBTS compared with NBTS 
laboratories. Of note, lower sensitivity to HCV-positivity using 
the EIA-4 was limited to a single reputable assay, suggesting 
a need to rule out poor technical performance or recording 
errors. After all laboratories had completed testing and the 
CDC International Laboratory Branch had evaluated the 
results, it conducted site visits at low-performing laboratories 
and developed recommendations for remediation.
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FIGURE. Adjusted mean estimates of sensitivity (A) and specificity (B) for identification of positive and negative challenge specimens for human 
immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV), by assay virus, assay type, and National Blood Transfusion 
Services (NTBS) laboratory status — seven African countries,* 2017†
RDT
EIA-3
EIA-4
0
10
20
30
40
50
60
70
80
90
100
Pe
rc
en
ta
ge
Laboratory status
A. Sensitivity
0
10
20
30
40
50
60
70
80
90
100
Pe
rc
en
ta
ge
Laboratory status
B. Specificity
HIV assay target HBV assay target HCV assay target HIV assay target HBV assay target HCV assay target
NTBS NTBS NTBSNTBSnon-
NTBS
NTBS NTBSnon-
NTBS
non-
NTBS
non-
NTBS
non-
NTBS
non-
NTBS
Abbreviations: EIA-3 = third generation enzyme immunoassay; EIA-4 = fourth generation enzyme immunoassay; RDT = rapid diagnostic test.
* Ghana, Kenya, Malawi, Mozambique, Nigeria, Rwanda, and Tanzania.
† 95% confidence intervals indicated by error bars.
The findings in this report are subject to at least four limita-
tions. First, the numbers of positive-challenge specimens per 
assay target virus were small, which resulted in few response 
levels for sensitivity estimations. Second, the positive samples 
were diluted to approximate difficult samples, but this limits 
extrapolation of operational sensitivity. Third, the investiga-
tors attempted to overcome sampling bias by using a random 
sample of non-NBTS laboratories; however, five of these 
laboratories failed to participate in the study, and six others 
submitted incomplete data, which suggests problems with 
their supplies of assay kits. Finally, the unanticipated strong 
association of assay type with NBTS status and few NBTS 
laboratories per country precluded fully distinguishing the 
effects of assay type, NBTS status, and country.
Variation in blood center laboratory proficiency among 
sub-Saharan African countries has been reported previously 
and likely relates to both assay quality, representing a range of 
manufacturers, and organizational structures, resources, and 
training of technicians (5–7). Future studies of testing profi-
ciency could be designed to study manufacturers in addition to 
assay type, with the aim of identifying products that perform 
poorly. Alternatively, future study protocols could provide 
high-accuracy assay kits targeting HIV, HBV, and HCV to 
better distinguish between assay quality and operator error.
To ensure that transfusion-transmitted viruses in donated 
blood are detected, the use of rapid diagnostic tests for HBV 
and HCV should be discouraged because of the general sub-
optimal performance of these assays. Where possible, scarce 
blood center resources should be allocated to enable all blood 
center laboratories to use EIA-based assays from selected 
manufacturers, improve the reliability of supply chains and 
implement standard quality assurance protocols for conducting 
the assays, and require technical staff members to participate 
in testing-proficiency training programs. However, quality 
improvements might be difficult to sustain if African national 
budgets are not supplemented by international funding (8).
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